These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://laylapyug505540.fireblogz.com/70434869/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide